Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Respiratory Research

Fig. 2

From: Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer

Fig. 2

Competing risk analysis. a. The cumulative incidence of venous thromboembolism (VTE) in non-small cell lung cancer (NSCLC) patients with and without EGFR mutations (P = 0.047) assessed by the competing risk analysis. b. The cumulative incidence of venous thromboembolism (VTE) among non-small cell lung cancer (NSCLC) patients with and without KRAS mutations (P = 0.180) assessed by the competing risk analysis

Back to article page